publication date: Jan. 8, 2021

NCI Trials

NCI Trials for Jan. 2021

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – NRG-HN008

Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NRG Oncology

Gillison, Maura Lianne

(713) 792-6363


Phase I/II – 10384

A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma

City of Hope Comprehensive Cancer Center LAO

Khodadoust, Michael Siavash

(650) 725-6451


Phase II – 10371

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

National Cancer Institute LAO

Chen, A P

(240) 781-3320


Phase II – A222001

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

Alliance for Clinical Trials in Oncology

Stish, Bradley J.

(507) 538-6120


Phase II – S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases


Brenner, Andrew Jacob

(210) 450-5936


Phase III – A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

Alliance for Clinical Trials in Oncology

Wei, Xiao X.

(617) 632-4524


Phase III – URCC-19185

Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

University of Rochester NCORP Research Base

Palesh, Oxana

(650) 725-7011

Copyright (c) 2020 The Cancer Letter Inc.